TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00132444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical vaginal application of UC-781 gel
Description: UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical vaginal application of UC-781 gel
Description: UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical vaginal application of UC-781 gel
Description: UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
Study: NCT02788175

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Entyvio (Vedolizumab)
Description: A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
Study: NCT05226650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular meal pattern
Description: 6 meals every day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Irregular meal pattern
Description: It consists of consuming a different number of meals every day (between 3 and 9).
Study: NCT02199691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 milliliter (mL), Intramuscular (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular (IM)
Study: NCT02461147

Intervention type: PROCEDURE
Intervention: Cholecystectomy with intraoperative cholangiogram
Description: cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
Study: NCT03004430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mantra Meditation
Description: Silent mantra meditation with spiritual mantra

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Progressive Muscle Relaxation
Study: NCT00661960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: 400mg tablet twice daily by mouth for nine months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz
Description: 600mg capsule once daily by mouth without regard to food
Study: NCT02199691

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant
Description: 0.5 mL, IM
Study: NCT01294618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.
Description: Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
Study: NCT01062685

Intervention type: DIAGNOSTIC_TEST
Intervention: Near-infrared spectroscopy assessment
Description: The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Near-infrared spectroscopy assessment
Description: The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Near-infrared spectroscopy assessment
Description: The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.~Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes.
Study: NCT03581136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dose Fractionation
Description: Patients will receive 5 fractions of radiation. These should not be on consecutive days. At least 40 hours between each fraction and a maximum of 21 days to complete, i.e.: Tuesday, Thursday, Monday, Wednesday, Friday.
Study: NCT06620926

Intervention type: OTHER
Intervention: IDH mutant-type
Description: The first arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.

Intervention type: OTHER
Intervention: IDH wild-type
Description: The second arm had IDH mutant-type, then stratified according to the treatment modality they received: adjuvant chemotherapy, adjuvant radiotherapy, adjuvant chemoradiotherapy.
Study: NCT00120380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aerosolized iloprost

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01046955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
Description: comparison of induction therapies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
Description: comparison of induction therapies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab
Description: comparison of induction therapies.
Study: NCT03609294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Fimasartan, Linagliptin)
Description: Co-administration of Fimasartan and Linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Fimasartan, Linagliptin)
Description: Co-administration of Fimasartan and Linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Fimasartan, Linagliptin)
Description: Co-administration of Fimasartan and Linagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Fimasartan/Linagliptin)
Description: Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Fimasartan/Linagliptin)
Description: Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B (Fimasartan/Linagliptin)
Description: Fixed Dose Combination of Fimasartan 120 mg/Linagliptin 5 mg
Study: NCT02344368

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.2 ml sucrose 25%
Description: Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.2 ml sucrose 25%
Description: Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.5 ml sucrose 25%
Description: Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.5 ml sucrose 25%
Description: Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
Study: NCT05750641

Intervention type: OTHER
Intervention: removing milk and dairy products from diets without medical treatment
Description: A specialist dietician prepared a diet list based on providing adequate balanced nutrition and is handed over to the diet group without any medical treatment

Intervention type: OTHER
Intervention: According to current standard algorithms and guidelines, appropriate treatment for FD types.
Description: According to current standard algorithms and guidelines, appropriate treatment for FD types was arranged for the patient group who preferred to receive a free diet
Study: NCT04486287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 12 months.~Before enrollment, patient should undergo Stereotactic Ablation Brachytherapy. Sintilimab shall be started no later than 4 weeks after Stereotactic Ablation Brachytherapy.
Study: NCT02078739

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Program at home using internet technology

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Program at home using internet technology
Study: NCT01581593

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Kedrion IVIG 10%
Description: Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
Study: NCT01138748

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy
Description: hypofractionated radiation therapy
Study: NCT04302571

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: combined aerobic and resistance physical activity
Description: Five training sessions weekly for 12 weeks are scheduled. Each session lasts 60 minutes divided into 45 minutes of aerobic workout and 15 minutes of circuit training. The aerobic workout consists of walking on a flat floor or on a slight uphill (maximum slope 3%): patients should walk until submaximal walking capacity (80% of their MWT) and rest as they would experience pain at the lower limbs; afterwards, they should start to walk again, once the pain was improved. Resistance training consists of calisthenics exercises focused on trunk and lower limbs muscles (bicycle, flutter kicks, squats, lunges, calf raises, wall sits and power press) with at least 3 repetitions for each exercise, interspersed by 30 seconds recovery. Duration of repetitions increases every 3 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham exercise
Description: general recommendation to perform regular aerobic physical activity
Study: NCT03798431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: M-ROCC
Description: 1. LDM (Low-Dose Mindfulness): A 4-wk intro mindfulness program for OUD, 50 min/week including explicit training in use of mobile mindfulness apps, with rolling admission and ascending practice dose ladder.~2. MTPC (Mindfulness Training for Primary Care): An eight-week intensive mindfulness group with ascending practice dose ladder and skill integration over 8 weeks \& 120 minutes/wk.~3. MCS (Mindfulness Maintenance Check-in Support): Ongoing weekly mindfulness group with check-in and reminders, leveraging mobile mindfulness apps and motivational counseling for grads of LDM for 50 mins/wk.~After completion of the LDM group, participation in various levels is fluid based on patient motivation, choice, and readiness.
Study: NCT02242877

Intervention type: DRUG
Intervention: Telmisartan

Intervention type: DRUG
Intervention: Telmisartan

Intervention type: DRUG
Intervention: Telmisartan combined with hydrochlorothiazide

Intervention type: DRUG
Intervention: Telmisartan combined with hydrochlorothiazide
Study: NCT04251559

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: oral glucose loading test
Description: oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: oral glucose loading test
Description: oral glucose loading test was performed to all participants. gestational diabetes and control group were compared in terms of menarche age.
Study: NCT04849949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group received a traditional muffin with butter as the predominant source of fat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black walnut
Description: Participants in this group received a muffin in which part of the butter was substituted out for black walnuts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: English walnut
Description: Participants in this group received a muffin in which part of the butter was substituted out for English walnuts.
Study: NCT04258839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Oral tablet; taken once daily
Study: NCT03488576

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete Macular Peeling
Description: A complete peeling of the internal limiting membrane was performed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Macular Peeling with Foveal Sparing
Description: A partial peeling of the internal limiting membrane was performed, sparing the fovea.
Study: NCT01175824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Low Mixture (LM)
Description: Participant-dependent dose, administered subcutaneously for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Participant-dependent dose, administered subcutaneously for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prandial Insulin Lispro
Description: Participant-dependent dose, administered subcutaneously for 24 weeks
Study: NCT02970968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLY-686 (Tradipitant)
Description: oral capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo oral
Study: NCT04453852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID19 vaccine
Description: COVID19 recombinant spike protein with Advax-SM adjuvant

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline control
Study: NCT04466514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029
Description: Form: tablet; Route of Administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029
Description: Form: tablet; Route of Administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX029
Description: Form: tablet; Route of Administration: oral
Study: NCT03444857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure
Description: The optimal continuous positive airway pressure (CPAP, AutoSet S9, ResMed, Sydney, Australia) settings will be determined during 1-2 nights within 7 days after pPCI.
Study: NCT01816139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Vehicle Cream applied to the vagina daily for 2 weeks followed by dosing 2 times a week for 10 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: WC3011 Estradiol Vaginal Cream
Description: WC3011 estradiol vaginal cream applied daily for 2 weeks followed by dosing 2 times a week for 10 weeks
Study: NCT02537080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine group
Description: the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control group
Description: the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
Study: NCT01111656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1b group
Description: Patients receive interferon beta-1b 250ug subcutaneously every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b/Atorvastatin group
Description: Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
Study: NCT02786615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Unity
Description: A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
Study: NCT06219655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracoscopic sympathectomy
Description: sympathectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracoscopic sympathectomy
Description: sympathectomy
Study: NCT01360034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
Study: NCT02012387

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active
Description: Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
Study: NCT02554331

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FP-CIT single-photon emission computed tomography
Description: FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation
Description: Assessment of:~* overall cognitive function~* executive functions~* visuospatial functions~* Nonverbal memory~* verbal memory~* Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~* Beck Depression Inventory

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological evaluation
Description: Assessment of:~* overall cognitive function~* executive functions~* visuospatial functions~* Nonverbal memory~* verbal memory~* Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities~* Beck Depression Inventory

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait recording with sensors
Description: Gait recording with sensors
Study: NCT02012387

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Open labeled
Description: Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
Study: NCT04380584

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma Apelin level
Description: blood sample for detection of plasma Apelin level

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma Apelin level
Description: blood sample for detection of plasma Apelin level

Intervention type: DIAGNOSTIC_TEST
Intervention: plasma Apelin level
Description: blood sample for detection of plasma Apelin level
Study: NCT02037503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study: NCT00785226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA119
Description: Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
Study: NCT02554331

Intervention type: OTHER
Group type: OTHER
Intervention: Gait recording with sensors
Description: Gait recording with sensors
Study: NCT04571164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003(Rotigotine,extended-release microspheres)
Description: During the intervention, the initial dose was 14mg, and then was incremented in weekly units, 14mg each time, until the maximum dose of 56mg set in this study was reached 4 weeks after titration, the optimal therapeutic dose or the maximum tolerated dose was entered into the dosing maintenance period. After entering the maintenance period, no dose adjustment was performed, and the stable dose was maintained for 24 weeks
Study: NCT00785226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
Study: NCT04898218

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The exercises were performed for 12 weeks, for the maximum of 6 days/week for Osteoanabolic group, 5 days/week for aerobic group and 3 days/ week for a resistance group as per ACSM, FITT protocol.